Cargando…

Rationale for Combining the BCL2 Inhibitor Venetoclax with the PI3K Inhibitor Bimiralisib in the Treatment of IDH2- and FLT3-Mutated Acute Myeloid Leukemia

In October 2020, the FDA granted regular approval to venetoclax (ABT-199) in combination with hypomethylating agents for newly-diagnosed acute myeloid leukemia (AML) in adults 75 years or older, or in patients with comorbidities precluding intensive chemotherapy. The treatment response to venetoclax...

Descripción completa

Detalles Bibliográficos
Autores principales:	Seipel, Katja, Brügger, Yvo, Mandhair, Harpreet, Bacher, Ulrike, Pabst, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9604078/ https://www.ncbi.nlm.nih.gov/pubmed/36293442 http://dx.doi.org/10.3390/ijms232012587

Ejemplares similares

Rationale for a Combination Therapy with the STAT5 Inhibitor AC-4-130 and the MCL1 Inhibitor S63845 in the Treatment of FLT3-Mutated or TET2-Mutated Acute Myeloid Leukemia
por: Seipel, Katja, et al.
Publicado: (2021)

MDM2- and FLT3-inhibitors in the treatment of FLT3-ITD acute myeloid leukemia, specificity and efficacy of NVP-HDM201 and midostaurin
por: Seipel, Katja, et al.
Publicado: (2018)

Rationale for a Combination Therapy Consisting of MCL1- and MEK-Inhibitors in Acute Myeloid Leukemia
por: Seipel, Katja, et al.
Publicado: (2019)

Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia
por: Maiti, Abhishek, et al.
Publicado: (2021)

The Cellular p53 Inhibitor MDM2 and the Growth Factor Receptor FLT3 as Biomarkers for Treatment Responses to the MDM2-Inhibitor Idasanutlin and the MEK1 Inhibitor Cobimetinib in Acute Myeloid Leukemia
por: Seipel, Katja, et al.
Publicado: (2018)

BMI1-Inhibitor PTC596 in Combination with MCL1 Inhibitor S63845 or MEK Inhibitor Trametinib in the Treatment of Acute Leukemia
por: Seipel, Katja, et al.
Publicado: (2021)

Hypomethylating agent and venetoclax with FLT3 inhibitor “triplet” therapy in older/unfit patients with FLT3 mutated AML
por: Yilmaz, Musa, et al.
Publicado: (2022)

HSP90 Inhibitor PU-H71 in Combination with BH3-Mimetics in the Treatment of Acute Myeloid Leukemia
por: Seipel, Katja, et al.
Publicado: (2023)

ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development
por: Cang, Shundong, et al.
Publicado: (2015)

Allosteric SHP2 inhibition increases apoptotic dependency on BCL2 and synergizes with venetoclax in FLT3- and KIT-mutant AML
por: Popescu, Bogdan, et al.
Publicado: (2023)

Combination strategies to overcome resistance to the BCL2 inhibitor venetoclax in hematologic malignancies
por: Yue, XiaoYan, et al.
Publicado: (2020)

AML under the Scope: Current Strategies and Treatment Involving FLT3 Inhibitors and Venetoclax-Based Regimens
por: Milnerowicz, Szymon, et al.
Publicado: (2023)

FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3/ITD acute leukemia cells through BIM activation
por: Zhu, Ruiqi, et al.
Publicado: (2021)

Mechanisms of action of the BCL-2 inhibitor venetoclax in multiple myeloma: a literature review
por: Cao, Qiang, et al.
Publicado: (2023)

Resistance to targeted therapies: delving into FLT3 and IDH
por: Desikan, Sai Prasad, et al.
Publicado: (2022)

Hematologic Tumor Cell Resistance to the BCL-2 Inhibitor Venetoclax: A Product of Its Microenvironment?
por: Leverson, Joel D., et al.
Publicado: (2018)

Potential Biomarkers for Treatment Response to the BCL-2 Inhibitor Venetoclax: State of the Art and Future Directions
por: Salah, Haneen T., et al.
Publicado: (2021)

(2R,3S)-Dihydroxybutanoic Acid Synthesis as a Novel Metabolic Function of Mutant Isocitrate Dehydrogenase 1 and 2 in Acute Myeloid Leukemia
por: Idle, Jeffrey R., et al.
Publicado: (2020)

A Phase II Study to Assess the Safety and Efficacy of the Dual mTORC1/2 and PI3K Inhibitor Bimiralisib (PQR309) in Relapsed, Refractory Lymphoma
por: Collins, Graham P., et al.
Publicado: (2021)

mTOR inhibitors sensitize multiple myeloma cells to venetoclax via IKZF3- and Blimp-1-mediated BCL-2 upregulation
por: Osada, Naoki, et al.
Publicado: (2021)

Overcoming Resistance to FLT3 Inhibitors in the Treatment of FLT3-Mutated AML
por: Lam, Stephen S.Y., et al.
Publicado: (2020)

Reciprocal sensitivity of diffuse large B-cell lymphoma cells to Bcl-2 inhibitors BIRD-2 versus venetoclax
por: Vervloessem, Tamara, et al.
Publicado: (2017)

AMP-Activated Protein Kinase Contributes to Apoptosis Induced by the Bcl-2 Inhibitor Venetoclax in Acute Myeloid Leukemia
por: Legrand, Noémie, et al.
Publicado: (2021)

A case report of complete remission of acute myeloid leukemia combined with DNMT3A, FLT3-TKD, and IDH2 gene mutations and active pulmonary tuberculosis treated with homeharringtonine + venetoclax + azacytidine
por: Ji, Lin, et al.
Publicado: (2023)

Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models
por: Mali, Raghuveer Singh, et al.
Publicado: (2020)

ABT‐199 (Venetoclax), a BH3‐mimetic Bcl‐2 inhibitor, does not cause Ca(2+)‐signalling dysregulation or toxicity in pancreatic acinar cells
por: Jakubowska, Monika A, et al.
Publicado: (2018)

Metabolic changes associated with metformin potentiates Bcl-2 inhibitor, Venetoclax, and CDK9 inhibitor, BAY1143572 and reduces viability of lymphoma cells
por: Chukkapalli, Vineela, et al.
Publicado: (2018)

OTS167 blocks FLT3 translation and synergizes with FLT3 inhibitors in FLT3 mutant acute myeloid leukemia
por: Eisfelder, Bartholomew J., et al.
Publicado: (2021)

FLT3 inhibition by olverembatinib (HQP1351) downregulates MCL-1 and synergizes with BCL-2 inhibitor lisaftoclax (APG-2575) in preclinical models of FLT3-ITD mutant acute myeloid leukemia
por: Fang, Douglas D., et al.
Publicado: (2021)

FLT3 inhibitors in acute myeloid leukemia
por: Wu, Mei, et al.
Publicado: (2018)

Inhibition of the Phosphatidylinositol-3 Kinase Pathway Using Bimiralisib in Loss-of-Function NOTCH1-Mutant Head and Neck Cancer
por: Johnson, Faye M, et al.
Publicado: (2022)

Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia
por: Daver, Naval, et al.
Publicado: (2022)

Efficacy and Safety of Bcl-2 Inhibitor Venetoclax in Hematological Malignancy: A Systematic Review and Meta-Analysis of Clinical Trials
por: Li, Qingfang, et al.
Publicado: (2019)

The BCL-2 inhibitor ABT-199/venetoclax synergizes with proteasome inhibition via transactivation of the MCL-1 antagonist NOXA
por: Weller, Sandra, et al.
Publicado: (2022)

The BCL2 Inhibitor Venetoclax Plus Rituximab Is Active in MYD88 Wild-Type Polyneuropathy With Anti-MAG Antibodies
por: Briani, Chiara, et al.
Publicado: (2022)

Co-expression of wild-type FLT3 attenuates the inhibitory effect of FLT3 inhibitor on FLT3 mutated leukemia cells
por: Chen, Fangli, et al.
Publicado: (2016)

High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibition
por: Bate-Eya, Laurel T., et al.
Publicado: (2016)

Venetoclax causes metabolic reprogramming independent of BCL-2 inhibition
por: Roca-Portoles, Alba, et al.
Publicado: (2020)

The immune regulation of BCL3 in glioblastoma with mutated IDH1
por: Fan, Shibing, et al.
Publicado: (2022)

FLT3 D835 Mutations Confer Differential Resistance to Type II FLT3 Inhibitors
por: Smith, Catherine C., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_i743fp6qi1dm4satv3qgefrrd7